Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07124221 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Sep 20, 2025 to Nov 21, 2026
    • Start date changed from estimate of Aug 30, 2025 to Sep 12, 2025
    • Site details revised
    v3
  2. Study title shortened, about 10 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia
Trial Details
NCT Number NCT07124221
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Hyperprolactinemia
Related terms Hyperprolactinemia
Enrollment 382 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov